Carlo Incerti MD
Operating Partner
A new class of powerful therapeutics for the treatment of severe diseases
Numab designs and develops powerful therapeutics for the treatment of severe diseases.
Their plug-and-play platform substantially reduces the random nature of the discovery process to predictably yield ready-to-develop multispecific biotherapeutics for chronic inflammation and cancer.
Industry
Biotech
Status
Current
Location
Switzerland
With Forbion's backing, we built a diversified pipeline of multi-specific therapeutics based on a differentiated platform. We mitigated risks through strategic partnerships in Asia and achieved a significant milestone by selling a therapy for atopic dermatitis to Johnson & Johnson for USD 1.25 billion in an all-cash upfront deal, while retaining our platform and remaining pipeline. Forbion's unwavering support and strategic guidance were instrumental in our success. They recognized Numab's potential early on, providing strong support on our board and remaining loyal and committed during challenging times.David Urech
CEO
12
Pharma partnerships
Forbion team
Nanna Lüneborg PhD, MBA
General Partner